Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla.

Talaris will present data on the makeup of patients’ peripheral blood mononuclear cells (PBMCs) following treatment with FCR001 in a subgroup of living donor kidney transplant (LDKT) patients enrolled in the Company’s Phase 3 FREEDOM-1 trial. A second presentation reflects findings from urinary cell mRNA profiling of a subgroup of Phase 2 patients.

The following are specific details regarding Talaris’ oral presentations:

Title: “A regimen of nonmyeloablative conditioning and CD8+/TCR- facilitating cells tips the balance towards immune down-regulation and away from cytopathic activity in kidney allograft recipients”

Presenter: John Lee, Weill Cornell Medicine

Number: SA-OR48

Session: Transplantation: Clinical Outcomes and Biomarkers

Date & Time: Saturday, November 5, 2022, 5:33 p.m. ET

Location: Orange County Convention Center, West Building, Room W240

Title: “Immune cell transcriptome in living-donor kidney transplant patients tolerized with allo-HSCT cell therapy”

Presenter: Jennifer McDaniels, University of Maryland, Baltimore

Number: SA-OR50

Session: Transplantation: Clinical Outcomes and Biomarkers

Date & Time: Saturday, November 5, 2022, 5:51 p.m. ET

Location: Orange County Convention Center, West Building, Room W240

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, a GMP cell processing facility in Louisville, KY, and research and development laboratories in Houston, TX.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Talaris Therapeutics, Inc.’s (“Talaris,” the “Company,” “we,” or “our”) strategy, business plans and focus; the progress and timing of the preclinical and clinical development of Talaris’ programs, including FCR001 and the rate of enrollment for its clinical trials; expectations regarding the timing and data from the planned clinical update of FREEDOM-1, FREEDOM-2 or FREEDOM-3, including potential safety, tolerability and therapeutics effects; expectations around the anticipated contribution of the members of Talaris’ board of directors and executives to its operations and progress; and expectations regarding Talaris’ growth as a company and use of capital, expenses and other financial results during the second quarter ended on June 30, 2022 and in the future as well as Talaris’ expected cash runway through 2024. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which the Company has operations or does business, as well as on the timing and anticipated timing and results of its clinical trials, strategy and future operations, including the expected timing and results from FREEDOM-1; the risk that the results of Talaris’ clinical trials, including the early data from the FREEDOM-1 study, may not be predictive of future results in connection with future clinical trials; the Company’s expectations regarding the potential urinary biomarker of immune quiescence, the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of Talaris’ planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Talaris’ views only as of today and should not be relied upon as representing our views as of any subsequent date. Talaris explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact

Lisa Raffensperger

Ten Bridge Communications

(617) 903-8783

Investor Contact

Chris Brinzey

ICR Westwicke

(339) 970-2843